MXC Stock Overview
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide.
Notes are coming soon
MGC Pharmaceuticals Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.011|
|52 Week High||AU$0.036|
|52 Week Low||AU$0.009|
|1 Month Change||-4.55%|
|3 Month Change||-25.00%|
|1 Year Change||-68.18%|
|3 Year Change||-67.19%|
|5 Year Change||-90.00%|
|Change since IPO||-92.76%|
Recent News & Updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?Jun 23
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?Mar 09
Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)Oct 08
If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% ReturnsFeb 21
What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?Dec 30
|MXC||AU Pharmaceuticals||AU Market|
Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: MXC underperformed the Australian Market which returned 3.5% over the past year.
|MXC Average Weekly Movement||16.4%|
|Pharmaceuticals Industry Average Movement||9.6%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.7%|
|10% least volatile stocks in AU Market||3.5%|
Stable Share Price: MXC is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: MXC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
MGC Pharmaceuticals Limited Fundamentals Summary
|MXC fundamental statistics|
Is MXC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MXC income statement (TTM)|
|Cost of Revenue||AU$4.17m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.007|
|Net Profit Margin||-430.00%|
How did MXC perform over the long term?See historical performance and comparison